182 related articles for article (PubMed ID: 26059273)
1. Methods for treating IL-6-related diseases (US2015010554A1): a patent evaluation.
Chin YW
Expert Opin Ther Pat; 2015; 25(9):1065-8. PubMed ID: 26059273
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of blocking IL-6 receptor.
Mima T; Nishimoto N
Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
[TBL] [Abstract][Full Text] [Related]
3. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
4. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
5. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab: the first interleukin-6-receptor inhibitor.
Sebba A
Am J Health Syst Pharm; 2008 Aug; 65(15):1413-8. PubMed ID: 18653811
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic uses of anti-interleukin-6 receptor antibody.
Kang S; Tanaka T; Kishimoto T
Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
[TBL] [Abstract][Full Text] [Related]
8. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy.
Atreya R; Billmeier U; Rath T; Mudter J; Vieth M; Neumann H; Neurath MF
World J Gastroenterol; 2015 Dec; 21(45):12963-9. PubMed ID: 26668517
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for the treatment of rheumatoid arthritis.
Tanaka T; Ogata A; Narazaki M
Expert Rev Clin Immunol; 2010 Nov; 6(6):843-54. PubMed ID: 20979549
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
15. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.
Mihara M; Nishimoto N; Ohsugi Y
Expert Opin Biol Ther; 2005 May; 5(5):683-90. PubMed ID: 15934843
[TBL] [Abstract][Full Text] [Related]
16. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Narazaki M; Tanaka T; Kishimoto T
Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
[TBL] [Abstract][Full Text] [Related]
17. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
18. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
Murakami M; Nishimoto N
Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
